Marshall Wace, LLP Eli Lilly & CO Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Eli Lilly & CO stock. As of the latest transaction made, Marshall Wace, LLP holds 910,132 shares of LLY stock, worth $679 Million. This represents 1.04% of its overall portfolio holdings.
Number of Shares
910,132
Previous 789,561
15.27%
Holding current value
$679 Million
Previous $715 Million
12.8%
% of portfolio
1.04%
Previous 0.99%
Shares
22 transactions
Others Institutions Holding LLY
# of Institutions
4,003Shares Held
752MCall Options Held
8.27MPut Options Held
10.5M-
Lilly Endowment Inc Indianapolis, IN96.9MShares$72.3 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA73.8MShares$55 Billion1.2% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$49.1 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$38.3 Billion29.2% of portfolio
-
State Street Corp Boston, MA33.9MShares$25.3 Billion1.24% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $709B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...